SUPERNUS PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
SUPN$27.62+5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Earnings
(in thousands)
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net earnings | $1,316 | $60,711 | $53,424 |
| Other comprehensive gain (loss): | |||
| Unrealized gain (loss) on marketable securities, net of tax | 2,617 | (4,749) | (7,436) |
| Other comprehensive gain (loss) | 2,617 | (4,749) | (7,436) |
| Comprehensive earnings | $3,933 | $55,962 | $45,988 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.